BOSSI, ELISA
BOSSI, ELISA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies
2024 Malighetti, F; Villa, M; Mauri, M; Piane, S; Crippa, V; Crespiatico, I; Cocito, F; Bossi, E; Steidl, C; Civettini, I; Scollo, C; Ramazzotti, D; Gambacorti-Passerini, C; Piazza, R; Mologni, L; Aroldi, A
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas
2023 Rindone, G; Aroldi, A; Bossi, E; Verga, L; Zambrotta, G; Tarantino, S; Piazza, R; Mussolin, L; Chiarle, R; Gambacorti-Passerini, C
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia
2023 Aroldi, A; Mauri, M; Ramazzotti, D; Villa, M; Malighetti, F; Crippa, V; Cocito, F; Borella, C; Bossi, E; Steidl, C; Scollo, C; Voena, C; Chiarle, R; Mologni, L; Piazza, R; Gambacorti Passerini, C
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi
2023 Zamprogna, G; Frustaci, A; Travi, G; Borella, C; Reda, G; Motta, M; Deodato, M; Bossi, E; Mattiello, V; Ferrari, M; Cotilli, G; Gambacorti-Passerini, C; Cairoli, R; Puoti, M; Tedeschi, A
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706)
2022 Bossi, E; Aroldi, A; Borin, L; Verga, L; Fontana, D; Cocito, F; Manghisi, B; Rindone, G; Cavalca, F; Ripamonti, A; Raggi, M; Malandrin, S; Cavallero, A; Antolini, L; Bonardi, D; Piazza, R; Gambacorti-Passerini, C
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization
2020 Crespiatico, I; Bossi, E; Brioschi, F; Piazza, R; Mologni, L; Gambacorti‐passerini, C
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy
2020 Bossi, E; Aroldi, A; Brioschi, F; Steidl, C; Baretta, S; Renso, R; Verga, L; Fontana, D; Sharma, G; Mologni, L; Mussolin, L; Piazza, R; Gambacorti Passerini, C
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy
2019 Bossi, E; Brioschi, F; Steidl, C; Baretta, S; Cantu, S; Verga, L; Fontana, D; Sharma, G; Mologni, L; Mussolin, L; Piazza, R; Gambacorti Passerini, C